Share on LinkedInShare on LinkedIn

ARTICLE · 10 JANUARY 2008

German Federal Patent Court Invalidates Pfizer’s LIPITOR® Patent

Invalidating all relevant claims of the patent-in-suit, the Federal Patent Court of Germany handed down a decision for Ranbaxy Laboratories’ German subsidiary Basics GmbH in its case against Warner Lambert’s European Patent 0,409,281 (EP ’281) owned by Pfizer [Reference-No: 3 Ni 36/05 (EU)].

GermanyIntellectual Property

Invalidating all relevant claims of the patent-in-suit, the Federal Patent Court of Germany handed down a decision for Ranbaxy Laboratories' German subsidiary Basics GmbH in its case against Warner Lambert's European Patent 0,409,281 (EP '281) owned by Pfizer [Reference-No: 3 Ni 36/05 (EU)].

EP '281 covered an enantiomer calcium salt which has a positive pharmaceutical effect in the treatment of hypercholesterolemia and hyperlipidemia. Pfizer marketed a cholesterol-lowering drug under the brand-name LIPITOR® (sold as "Sortis" in Germany) covered by EP '281. The Court found that the subject matter of claims 1 through 3 is not novel due to prior art citations in U.S. Patent No. 4,681,893 (US '893) as well as in WO 89/07 598 A2 (WO '598). Further, the Court held that claim 4 does not amount to an inventive step in view of U.S. Patent No. 4,375,475 (US '475) and US '893, as well as a 1987 publication in

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from